Read Why Barclays Analyst Is 'Negatively Biased' On Kodiak Sciences

Barclays has lowered the firm's price target on Kodiak Sciences Inc KOD to $50 from $81 and keeps an Underweight rating on the shares, representing an almost 20% downside.

  • The analyst dropped the price target to reflect a lower probability of success and lower peak penetrations.
  • After conducting a "deep dive" ahead of the "binary catalyst: of the KSI- 301 Phase 2/3 DAZZLE study in wet macular degeneration in late Q1, analyst Gena Wang continues to be "negatively biased." 
  • Last week, the Company completed enrollment in its GLEAM and GLIMMER Phase 3 trials of KSI-301, Kodiak's anti-VEGF antibody biopolymer conjugate, in diabetic macular edema (DME). 
  • The Company says topline data from the DAZZLE trial is expected this quarter and mid-year for BEACON.
  • KSI-301 is an investigational anti-VEGF therapy built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform. It is designed to maintain potent and effective drug levels in ocular tissues for longer than available agents. 
  • Price Action: KOD shares are down 0.26% at $63.62 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: BiotechNewsHealth CarePrice TargetAnalyst RatingsGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!